Oncotarget

Research Papers:

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma

Shugo Ueda _, Yoshihiro Miyahara, Yasuhiro Nagata, Eiichi Sato, Taizo Shiraishi, Naozumi Harada, Hiroaki Ikeda, Hiroshi Shiku and Shinichi Kageyama

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:35997-36011. https://doi.org/10.18632/oncotarget.26323

Metrics: PDF 363 views  |   HTML 671 views  |   ?  


Abstract

Shugo Ueda1, Yoshihiro Miyahara2, Yasuhiro Nagata3, Eiichi Sato4, Taizo Shiraishi5, Naozumi Harada6, Hiroaki Ikeda7, Hiroshi Shiku8 and Shinichi Kageyama9

1Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Kita-ku, Osaka 530-8480, Japan

2Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan

3Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan

4Department of Pathology, Institute of Medical Science, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan

5Department of Oncologic Pathology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan

6United Immunity, Co., Ltd., Tsu, Mie 514-8507, Japan

7Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan

8Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan

9Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan

Correspondence to:

Shugo Ueda, email: shu-ueda@kitano-hp.or.jp

Shinichi Kageyama, email: kageyama@clin.medic.mie-u.ac.jp

Keywords: cancer vaccine; MAGE-A4; NY-ESO-1; immune response; esophageal cancer

Received: July 27, 2018     Accepted: October 25, 2018     Published: November 13, 2018

ABSTRACT

MAGE-A4 antigen is a cancer-testis antigen that is frequently expressed in tumor tissues. Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received a CHP-MAGE-A4 vaccine. Twenty-two patients with advanced or metastatic cancer were enrolled, and were subcutaneously vaccinated with either 100 μg or 300 μg of CHP-MAGE-A4. Seven and 15 patients, respectively, were repeatedly vaccinated with 100 μg or 300 μg of CHP-MAGE-A4; patients in both groups received a median of 7 doses. No serious adverse events related to the vaccine were observed. Of 7 patients receiving the 100 μg dose, 2 (29%) showed immune responses, compared with 3 of the 14 (21%) patients who received the 300 μg dose. In total, MAGE-A4-specific antibody responses were induced in 5 of 21 (24%) patients. No differences in survival were seen between patients receiving the 100 μg and 300 μg doses, or between immune responders and non-responders. Eleven (50%) patients had pre-existing antibodies to NY-ESO-1. In 16 patients with esophageal or head/neck squamous cell carcinoma, the survival time was significantly shorter in those who had NY-ESO-1-co-expressing tumors. Patients with high pre-existing antibody responses to NY-ESO-1 displayed worse prognosis than those with no pre-existing response. Therefore, in planning clinical trials of MAGE-A4 vaccine, enrolling NY-ESO-1-expressing tumor or not would be a critical issue to be discussed. Combination vaccines of MAGE-A4 and NY-ESO-1 antigens would be one of the strategies to overcome the poor prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26323